烟酰胺在帕金森病中的应用一条通往未来的可能之路。评论文章

Sarah Fahmy, Mona Alshahawy, Nourhan S. Mohamed, Nora Gamal, S. Abdelazim, Nadia Abdelsalam, Hend Abdelrahim, Reem Shehab, L. E. El Wakeel
{"title":"烟酰胺在帕金森病中的应用一条通往未来的可能之路。评论文章","authors":"Sarah Fahmy, Mona Alshahawy, Nourhan S. Mohamed, Nora Gamal, S. Abdelazim, Nadia Abdelsalam, Hend Abdelrahim, Reem Shehab, L. E. El Wakeel","doi":"10.21608/aps.2023.204521.1116","DOIUrl":null,"url":null,"abstract":"Increasing the prevalence of Parkinson‘s disease is an alarming sign that needs attention, so focusing on new medications and regimens which play an important role in prevention and treatment becomes a point of concern. Parkinson's disease is the second neurodegenerative disorder caused by the interplay between different mechanisms that are related to genetics, environment, and other factors. One of the potential treatment options under research is nicotinamide which may act as a neuroprotective agent. Although nicotinamide is accepted as a therapeutic agent in many diseases, its action as a Nicotinamide adenine dinucleotide (NAD) precursor against oxidative stress needs to be proved in Parkinson‘s disease. Here, based on the current literature, we provide a thorough overview of nicotinamide usage in medicine. We summarize chemistry, uses, side effects, different mechanisms, and all available preclinical and clinical data about the activity of nicotinamide. Nicotinamide increases cytoprotection, the release of dopamine, and decreases oxidative stress of mitochondria. As a consequence, we believe that nicotinamide may become a potential drug in the treatment of Parkinson‘s patients.","PeriodicalId":8314,"journal":{"name":"Archives of Pharmaceutical Sciences Ain Shams University","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The use of Nicotinamide in Parkinson’s disease; A Possible path to the future. Review Article\",\"authors\":\"Sarah Fahmy, Mona Alshahawy, Nourhan S. Mohamed, Nora Gamal, S. Abdelazim, Nadia Abdelsalam, Hend Abdelrahim, Reem Shehab, L. E. El Wakeel\",\"doi\":\"10.21608/aps.2023.204521.1116\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Increasing the prevalence of Parkinson‘s disease is an alarming sign that needs attention, so focusing on new medications and regimens which play an important role in prevention and treatment becomes a point of concern. Parkinson's disease is the second neurodegenerative disorder caused by the interplay between different mechanisms that are related to genetics, environment, and other factors. One of the potential treatment options under research is nicotinamide which may act as a neuroprotective agent. Although nicotinamide is accepted as a therapeutic agent in many diseases, its action as a Nicotinamide adenine dinucleotide (NAD) precursor against oxidative stress needs to be proved in Parkinson‘s disease. Here, based on the current literature, we provide a thorough overview of nicotinamide usage in medicine. We summarize chemistry, uses, side effects, different mechanisms, and all available preclinical and clinical data about the activity of nicotinamide. Nicotinamide increases cytoprotection, the release of dopamine, and decreases oxidative stress of mitochondria. As a consequence, we believe that nicotinamide may become a potential drug in the treatment of Parkinson‘s patients.\",\"PeriodicalId\":8314,\"journal\":{\"name\":\"Archives of Pharmaceutical Sciences Ain Shams University\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Archives of Pharmaceutical Sciences Ain Shams University\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.21608/aps.2023.204521.1116\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Archives of Pharmaceutical Sciences Ain Shams University","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.21608/aps.2023.204521.1116","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

帕金森氏症患病率的增加是一个令人担忧的迹象,需要引起注意,因此关注在预防和治疗中发挥重要作用的新药物和方案成为一个值得关注的问题。帕金森病是第二种神经退行性疾病,由与遗传、环境和其他因素相关的不同机制相互作用引起。正在研究的一种潜在的治疗方案是烟酰胺,它可能起到神经保护剂的作用。虽然烟酰胺被公认为许多疾病的治疗药物,但其作为烟酰胺腺嘌呤二核苷酸(NAD)前体抗氧化应激的作用需要在帕金森病中得到证实。在此,基于目前的文献,我们提供了烟酰胺在医学上的使用的全面概述。我们总结了烟酰胺的化学,用途,副作用,不同的机制,以及所有可用的临床前和临床数据。烟酰胺增加细胞保护,释放多巴胺,减少线粒体的氧化应激。因此,我们相信烟酰胺可能成为治疗帕金森患者的潜在药物。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
The use of Nicotinamide in Parkinson’s disease; A Possible path to the future. Review Article
Increasing the prevalence of Parkinson‘s disease is an alarming sign that needs attention, so focusing on new medications and regimens which play an important role in prevention and treatment becomes a point of concern. Parkinson's disease is the second neurodegenerative disorder caused by the interplay between different mechanisms that are related to genetics, environment, and other factors. One of the potential treatment options under research is nicotinamide which may act as a neuroprotective agent. Although nicotinamide is accepted as a therapeutic agent in many diseases, its action as a Nicotinamide adenine dinucleotide (NAD) precursor against oxidative stress needs to be proved in Parkinson‘s disease. Here, based on the current literature, we provide a thorough overview of nicotinamide usage in medicine. We summarize chemistry, uses, side effects, different mechanisms, and all available preclinical and clinical data about the activity of nicotinamide. Nicotinamide increases cytoprotection, the release of dopamine, and decreases oxidative stress of mitochondria. As a consequence, we believe that nicotinamide may become a potential drug in the treatment of Parkinson‘s patients.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
15
审稿时长
12 weeks
期刊最新文献
Mechanisms and Protective Strategies in Cognitive Impairment Induced by Combination of Doxorubicin and Cyclophosphamide Chemobrain: Insight the possible mechanisms of action induced by chemotherapeutic agents. A Comprehensive Review of the Pathophysiology of Depression Extremely low frequency electromagnetic field (ELF-EMF) as a promising tool for treatment against multi-drug resistant bacteria Evaluation of the antibacterial, antibiofilm, and cytotoxic activities of Peltophorum africanum leaf methanolic extract
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1